As a pioneer in the field of liver related elastography, FibroScan® is recognized worldwide as the non-invasive solution for a comprehensive management of liver health with more than 2,500 peer reviewed publications.
Our one-of-a-kind parameters
LSM by VCTE™ (Liver Stiffness Measurement by Vibration-Controlled Transient Elastography), CAP™ (controlled attenuation parameter) and SSM by VCTE™ (Spleen Stiffness Measurement) enable point of care, non-invasive diagnosis and monitoring.
LSM by VCTE™ is unique, patented and validated for Liver Stiffness Measurement1.
2,250 peer-reviewed publications support the use of LSM by VCTE™.
CAPTM is unique patented and validated for liver disease management.
330 international peer-reviewed publications support the use of CAP™.
SSM by VCTE™ is a unique, patented and validated new marker for Spleen Stiffness Measurement.
100 peer-reviewed publications support the use of SSM by VCTE™.
2,500 peer-reviewed publications and more than 70 international guidelines evaluating, reporting or citing LSM by VCTE™ and CAP™.
VCTE™ can be used to accurately diagnose cirrhosis at an acceptable rate of false negatives and false positives in patients with chronic liver disease.
CAP™ is a point-of-care, standardized and reproducible technique, promising for the detection of liver steatosis.
TE is an established technique and is recommended as the initial assessment for significant liver fibrosis and cirrhosis (A1).
TE is a highly reproducible and user-friendly technique for assessing liver fibrosis in patients with chronic liver disease.
TE can be considered the non-invasive standard for the measurement of liver stiffness.
TE: Most widely used and validated technique for measurement of liver stiffness: standard to be beaten.
Vibration-controlled transient elastography (VCTE) is the most commonly used imaging-based fibrosis assessment method in the United States.
It has been validated in large cohorts worldwide in a spectrum of liver diseases, including hepatitis B, hepatitis C, fatty liver disease and autoimmune liver disorders, among others.